{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:32:21Z","timestamp":1788931941992,"version":"build-2803163510"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1001\/jamaophthalmol.2020.5044","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T17:57:29Z","timestamp":1605808649000},"page":"57","source":"Crossref","is-referenced-by-count":40,"title":["Insights From Survival Analyses During 12 Years of Anti\u2013Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"139","author":[{"given":"Dun Jack","family":"Fu","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarnan D.","family":"Keenan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Faes","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"},{"name":"Eye Clinic of the Cantonal Hospital of Lucerne, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Lim","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried K.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moraes","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Huemer","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"},{"name":"Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kern","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"},{"name":"Department of Ophthalmology, University Hospital of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Balaskas","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn A.","family":"Sim","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"},{"name":"School of Population Health and Environmental Sciences, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[{"name":"Gloucestershire Retinal Research Group, Gloucester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Stratton","sequence":"additional","affiliation":[{"name":"National Institute for Health and Research Biomedical Center, Moorfields Eye Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom"},{"name":"University College London Institute of Ophthalmology, London, United Kingdom"},{"name":"School of Population Health and Environmental Sciences, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi200091r1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"5","key":"eoi200091r2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group.","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200091r3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.survophthal.2005.12.001","article-title":"The role of inflammation in the pathogenesis of age-related macular degeneration.","volume":"51","author":"Donoso","year":"2006","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"eoi200091r4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200091r5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial.","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi200091r6","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.ophtha.2016.05.054","article-title":"Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761).","volume":"124","author":"Gillies","year":"2017","journal-title":"Ophthalmology"},{"key":"eoi200091r7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2288-14-118","article-title":"Handling missing data in RCTs; a review of the top medical journals.","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"eoi200091r8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12874-020-00930-2","article-title":"A framework for extending trial design to facilitate missing data sensitivity analyses.","volume":"20","author":"Mason","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"eoi200091r9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","article-title":"A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.","volume":"117","author":"Gupta","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200091r10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92?976 ranibizumab injections: report 1: visual acuity.","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200091r11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study.","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200091r12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12874-020-00936-w","article-title":"Power difference in a ?2 test vs generalized linear mixed model in the presence of missing data: a simulation study.","volume":"20","author":"Miller","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"eoi200091r13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/bjophthalmol-2015-307821","article-title":"Ophthalmic statistics note 8: missing data\u2013exploring the unknown.","volume":"100","author":"Bunce","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"eoi200091r14","article-title":"Fallacies of last observation carried forward analyses.","author":"Lachin","journal-title":"Clin Trials"},{"issue":"2","key":"eoi200091r16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","article-title":"Survival analysis part I: basic concepts and first analyses.","volume":"89","author":"Clark","year":"2003","journal-title":"Br J Cancer"},{"key":"eoi200091r17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ajo.2016.06.021","article-title":"Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration.","volume":"169","author":"Inoue","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi200091r18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oret.2018.08.003","article-title":"The incidence of neovascularization in the fellow eye of patients with unilateral choroidal lesion: a survival analysis.","volume":"3","author":"Bochicchio","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"eoi200091r19","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/820605","article-title":"Long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections.","volume":"2015","author":"Calvo","year":"2015","journal-title":"J Ophthalmol"},{"issue":"5","key":"eoi200091r20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/ceo.v48.5","article-title":"Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: a single-centre French study.","volume":"48","author":"Wolff","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"eoi200091r21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions.","volume":"210","author":"Gillies","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"eoi200091r24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2147\/OPTH","article-title":"International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease.","volume":"4","author":"Bron","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"eoi200091r25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/archopht.122.1.84","article-title":"The impact of diabetic retinopathy on participation in daily living.","volume":"122","author":"Lamoureux","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi200091r26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027441","article-title":"One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.","volume":"9","author":"Fasler","year":"2019","journal-title":"BMJ Open"},{"issue":"20","key":"eoi200091r27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"eoi200091r28","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"issue":"2","key":"eoi200091r29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40123-018-0139-5","article-title":"Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: evidence from a clinical setting.","volume":"7","author":"Eleftheriadou","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"eoi200091r31","doi-asserted-by":"crossref","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study.","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"eoi200091r32","doi-asserted-by":"crossref","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"eoi200091r33","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration.","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi200091r35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","article-title":"Defining a minimum set of standardized patient-centered outcome measures for macular degeneration.","volume":"168","author":"Rodrigues","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi200091r36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","article-title":"Two year outcomes of \u201ctreat and extend\u201d intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration.","volume":"38","author":"Barthelmes","year":"2018","journal-title":"Retina"},{"key":"eoi200091r37","first-page":"14","article-title":"Five-year outcomes with anti-vascular endothelial growth factor in neovascular age-related macular degeneration: results of the Comparison of Age-related Macular Degeneration Treatments Trials.","volume":"2(3)","author":"Mathis","year":"2017","journal-title":"Ann Eye Sci"},{"issue":"12","key":"eoi200091r38","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/bjophthalmol-2016-309818","article-title":"UK AMD\/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.","volume":"101","author":"Lee","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"eoi200091r39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"eoi200091r40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/00019053-199915050-00001","article-title":"Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies.","volume":"15","author":"Revicki","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"7172","key":"eoi200091r41","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method).","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"key":"eoi200091r42","author":"Moons","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"eoi200091r43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamaophthalmol.2019.4782","article-title":"Clinical practice settings vs clinical trials: is artificial intelligence the answer?","volume":"138","author":"Jampol","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi200091r44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/ebn.9.3.68","article-title":"The GATE frame: critical appraisal with pictures.","volume":"9","author":"Jackson","year":"2006","journal-title":"Evid Based Nurs"},{"issue":"12","key":"eoi200091r45","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"issue":"7","key":"eoi200091r46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA.","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"eoi200091r47","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00417-018-3907-y","article-title":"The fate of eyes with wet AMD beyond four years of anti-VEGF therapy.","volume":"256","author":"Garweg","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"eoi200091r48","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","article-title":"Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.","volume":"34","author":"Chandra","year":"2020","journal-title":"Eye (Lond)"},{"issue":"8","key":"eoi200091r49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/aos.13522","article-title":"An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.","volume":"95","author":"Berg","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"eoi200091r50","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3207614","article-title":"Long-term visual outcomes for a treat-and-extend antivascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration: up to seven-year follow-up.","volume":"2020","author":"Javidi","year":"2020","journal-title":"J Ophthalmol"},{"key":"eoi200091r51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajo.2015.11.002","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: The SEVEN-UP Study.","volume":"162","author":"Brijesh","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi200091r52","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","article-title":"Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections.","volume":"40","author":"Starr","year":"2020","journal-title":"Retina"},{"key":"eoi200091r53","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2020.05.005","article-title":"Long-term follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections.","author":"Kung","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"eoi200091r54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/aos.v98.2","article-title":"Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.","volume":"98","author":"Brynskov","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"eoi200091r15","doi-asserted-by":"crossref","volume-title":"Practical Statistics for Medical Research","author":"Altman","DOI":"10.1201\/9780429258589"},{"key":"eoi200091r30"},{"key":"eoi200091r22","unstructured":"American Academy of Ophthalmology. Vision rehabilitation preferred practice pattern. Published 2017. Accessed August 11, 2019. https:\/\/www.aao.org\/Assets\/5872cf6f-104c-4a7a-a9f7-7a2bf506112a\/636492820096070000\/vision-rehabilitation-final-12-19-17-pdf"},{"key":"eoi200091r23","unstructured":"International Council of Ophthalmology. Visual standards: aspects and ranges of vision loss with emphasis on population surveys. Report presented at: 29th International Congress of Ophthalmology; April 2002; Sydney, Australia. Accessed August 14, 2019. http:\/\/www.icoph.org\/downloads\/visualstandardsreport.pdf"},{"key":"eoi200091r34","unstructured":"US Food & Administration. Drug approval package: Lucentis (ranibizumab) injection. Updated September 26, 2006. Accessed August 21, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125156s0000_LucentisTOC.cfm"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2772986\/jamaophthalmology_fu_2020_oi_200091_1610718707.7998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T22:06:58Z","timestamp":1669673218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2772986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5044","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}